Anti-TNF compounds
AssigneeExicure, Inc.
InventorsChristopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
Life of this patent
Estimating the term…
Abstract
TNFα antisense oligonucleotides are provided herein. Methods of treating TNFα diseases or disorders using the TNFα antisense oligonucleotides and related products are provided.
Claims42
A compound comprising the structure depicted in FIG. 7, SEQ ID NO. 16, or salts thereof, of 18-19 nucleotides in length wherein the compound includes at least one phosphorothioate modification.
An oligonucleotide comprising mUmGmGmGmAmGT*A*G*A*T*G*mAmGmGmUmAmC (SEQ ID NO. 16), wherein the oligonucleotide is 18 nucleotides in length, wherein m is a 2′O methyl, and wherein * is a phosphorothioate modification.
An oligonucleotide comprising 5′ TGGGAGTAGATGAGGTAC 3′ (SEQ ID NO. 4), wherein the oligonucleotide is 18-19 nucleotides in length, wherein 4-6 nucleotides at the 5′ end and 4-6 nucleotides at the 3′ end of the oligonucleotide include a 2′O methyl, and wherein 4-10 nucleotides have a phosphorothioate modification.
A stable self-assembling nanostructure, comprising
- an antisense oligonucleotide of 18-19 nucleotides in length comprising TGGGAGTAGATGAGGTAC (SEQ ID NO. 4), wherein the antisense oligonucleotide is associated with a core.
A stable self-assembling nanostructure, comprising an antisense oligonucleotide of 18-19 nucleotides in length comprising TGGGAGTAGATGAGGTAC (SEQ ID NO. 4), wherein a hydrophobic group at the 3′ or 5′ terminus self-associates to form the core of the nanostructure in water or other suitable solvents.
Dependencies are inferred from the claim text.